<DOC>
	<DOCNO>NCT02253953</DOCNO>
	<brief_summary>Assessment effect two time oral 100 mg ritonavir capsule pharmacokinetics single dose BILR 355 BS dissolve PEG 400</brief_summary>
	<brief_title>Pharmacokinetics Single Doses BILR 355 BS Given With Ritonavir Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Ritonavir</mesh_term>
	<criteria>All participant study healthy male Age range 21 50 year Body mass index ( BMI ) within 18.5 29.9 kg/m2 In accordance Good Clinical Practice local legislation volunteer give write informed consent prior admission study Any finding medical examination ( include blood pressure , pulse rate ECG ) deviate normal clinical relevance Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder History orthostatic hypotension , faint spell blackouts Chronic relevant acute infection History allergy/hypersensitivity ( include drug allergy ) deem relevant trial judge investigator Intake drug long halflife ( &gt; 24 hour ) within least one month less ten halflives respective drug enrolment study study Use drug might influence result trial 7 day prior enrolment study study Participation another trial investigational drug ( ≤ two month prior administration trial ) Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) Inability refrain smoke trial day Alcohol abuse ( &gt; 60 g/day ) Drug abuse Blood donation ( ≥ 100 mL within four week prior administration trial ) Any laboratory value outside clinically accept reference range Excessive physical activity within last week trial trial Following exclusion criterion special interest study : Erythema , exanthema comparable skin alteration</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>